2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Eberhard F. Mammen (1930–2008).

Welcome to the latest of our Eberhard F. Mammen award announcements. As noted previously,[1] [2] [3] Thieme, the publisher of Seminars in Thrombosis & Hemostasis, has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard F. Mammen and in recognition of his contribution to this field and to the journal that he both founded and steered for more than three decades. These awards began in 2009, under two categories: “Most Popular Article Awards” and “Young Investigator Awards.” Current details and conditions of the award can be summarized as:

• Most Popular article awards: Awarded to the authors of the most popular articles published in Seminars in Thrombosis & Hemostasis. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, Errata, Letters to the Editor, Editorials, and previous award winners are excluded from further consideration of these awards, which currently comprise two categories: one for “open access” articles and another for a “general category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “general category” awards are granted “open access” status for these articles thereafter.

• Young Investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other article related to the topic of their presentation for publication in Seminars in Thrombosis & Hemostasis.

Further details of the awards and the award winners are posted online (http://www.thieme.com/sth), and previous award winner announcements are also available in print.[4] [5] [6] [7] [8] [9] [10] [11]

It is, therefore, with great pleasure that we would like to announce the latest winners of the 2015 Eberhard F. Mammen awards for the most popular articles from Seminars in Thrombosis & Hemostasis for the period of 2013 to 2014 inclusive. We will be announcing the young investigator awards related to meetings held in the recent past at a forthcoming opportunity.

• References

• 1 Favaloro EJ. Editorial. Welcome to a special issue of Seminars in Thrombosis & Hemostasis—The Closing Issue for 2008. Semin Thromb Hemost 2008; 34: 693-696
• 2 Favaloro EJ. Preface. A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008; 34 (8) 703-707
• 3 Favaloro EJ. Editorial. Welcome to the first issue of Seminars in Thrombosis & Hemostasis for 2009. Semin Thromb Hemost 2009; 35: 1-2
• 4 Favaloro EJ. Editorial. Winners of the inaugural Eberhard F. Mammen award for most popular article. Semin Thromb Hemost 2009; 35: 587-590
• 5 Favaloro EJ. Editorial. 2009 Eberhard F. Mammen young investigator award winners. Semin Thromb Hemost 2010; 36: 469-470
• 6 Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008-2009. Semin Thromb Hemost 2010; 36 (7) 685-692
• 7 Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011; 37 (5) 431-439
• 8 Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012; 38 (5) 425-432
• 9 Favaloro EJ. 2013 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2013; 39 (6) 567-574
• 10 Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part I - most popular articles. Semin Thromb Hemost 2014; 40 (4) 407-412
• 11 Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part II-Young Investigator Awards. Semin Thromb Hemost 2014; 40 (7) 718-723
• 12 Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost 2013; 39 (4) 452-458
• 13 George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 2013; 39 (2) 153-160
• 14 Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013; 39 (5) 559-566
• 15 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39 (6) 585-595
• 16 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (8) 865-883
• 17 Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 2013; 39 (2) 191-201
• 18 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39 (7) 772-778
• 19 Barbano B, Gigante A, Amoroso A, Cianci R. Thrombosis in nephrotic syndrome. Semin Thromb Hemost 2013; 39 (5) 469-476
• 20 Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2010; 36 (8) 807-818
• 21 McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost 2013; 39 (1) 101-111
• 22 Barco S, Nijkeuter M, Middeldorp S. Pregnancy and venous thromboembolism. Semin Thromb Hemost 2013; 39 (5) 549-558
• 23 Franchini M, Coppola A, Rocino A , et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39 (7) 752-766
• 24 Tagalakis V, Wharin C, Kahn SR. Comprehensive update on the prevention and treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost 2013; 39 (2) 127-140
• 25 Monagle P. Diagnosis and management of deep venous thrombosis and pulmonary embolism in neonates and children. Semin Thromb Hemost 2012; 38 (7) 683-690
• 26 Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost 2003; 29 (5) 435-450
• 27 Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39 (6) 632-641
• 28 Lippi G, Mattiuzzi C, Favaloro EJ. Novel and emerging therapies: thrombus-targeted fibrinolysis. Semin Thromb Hemost 2013; 39 (1) 48-58
• 29 Declerck PJ, Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost 2013; 39 (4) 356-364
• 30 Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost 2012; 38 (5) 454-462
• 31 Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013; 39 (6) 621-631
• 32 Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28 (3) 247-256
• 33 Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost 2013; 39 (7) 840-846
• 34 Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. Semin Thromb Hemost 2011; 37 (3) 237-251
• 35 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30 (5) 579-589
• 36 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2012; 38 (5) 483-496
• 37 Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. Semin Thromb Hemost 2010; 36 (1) 59-70
• 38 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31 (4) 381-392
• 39 Rak J. Microparticles in cancer. Semin Thromb Hemost 2010; 36 (8) 888-906
• 40 Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009; 35 (4) 400-406
• 41 Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost 2013; 39 (2) 147-152
• 42 Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011; 37 (3) 267-274
• 43 Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013; 39 (2) 117-126
• 44 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012; 38 (7) 673-682
• 45 Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost 2011; 37 (3) 280-297
• 46 Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014; 40 (1) 60-65
• 47 Italiano Jr JE. Unraveling mechanisms that control platelet production. Semin Thromb Hemost 2013; 39 (1) 15-24
• 48 Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012; 38 (1) 23-30
• 49 Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 2014; 40 (1) 106-114
• 50 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (8) 709-733
• 51 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012; 38 (1) 47-54
• 52 Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35 (2) 189-203
• 53 Bunimov N, Fuller N, Hayward CP. Genetic loci associated with platelet traits and platelet disorders. Semin Thromb Hemost 2013; 39 (3) 291-305
• 54 Kenet G, Aronis S, Berkun Y , et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 2011; 37 (7) 802-809
• 55 Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. Semin Thromb Hemost 2014; 40 (1) 121-128
• 56 Raskob GE, Angchaisuksiri P, Blanco AN , et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost 2014; 40 (7) 724-735
• 57 Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2014; 40 (3) 277-283
• 58 Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost 2008; 34 (8) 772-778
• 59 Fareed J, Hoppensteadt DA, Fareed D , et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008; 34 (1) 58-73
• 60 Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014; 40 (2) 163-171
• 61 Harenberg J, Kraemer S, Du S , et al. Determination of direct oral anticoagulants from human serum samples. Semin Thromb Hemost 2014; 40 (1) 129-134